FBRX
Forte Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$76.99
+0.00%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+303.7%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 6, 2026 | Wagner Paul A. · director, officer: SEE REMARKS | M-Exempt | 1,250 | $0.00 |
| Jul 6, 2026 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | F-InKind | 134 | $21 |
| Jul 6, 2026 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 375 | $0.00 |
| Jul 6, 2026 | Wagner Paul A. · director, officer: SEE REMARKS | F-InKind | 98 | $21 |
| Jun 17, 2026 | Wagner Paul A. · director, officer: SEE REMARKS | A-Award | 500,000 | $17 |
| Jun 17, 2026 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | A-Award | 22,000 | $17 |
| Jun 2, 2026 | VINCENT RICHARD G · director | A-Award | 18,353 | $0.00 |
| Jun 2, 2026 | GRYSKA DAVID W · director | A-Award | 18,353 | $0.00 |
| Jun 2, 2026 | Brun Scott C. · director | A-Award | 18,353 | $0.00 |
| Jun 2, 2026 | Kornfeld Steven · director | A-Award | 18,353 | $0.00 |
| Jun 2, 2026 | Doberstein Stephen K · director | A-Award | 18,353 | $0.00 |
| Jun 2, 2026 | Kapoor Shivpreet Singh · director | A-Award | 18,353 | $0.00 |
| Apr 3, 2026 | Wagner Paul A. · director, officer: SEE REMARKS | F-InKind | 98 | $25 |
| Apr 3, 2026 | Wagner Paul A. · director, officer: SEE REMARKS | M-Exempt | 1,250 | $0.00 |
| Apr 3, 2026 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | F-InKind | 134 | $25 |
| Apr 3, 2026 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 375 | $0.00 |
| Jan 13, 2026 | Wagner Paul A. · director, officer: SEE REMARKS | A-Award | 180,000 | $0.00 |
| Jan 13, 2026 | Wagner Paul A. · director, officer: SEE REMARKS | A-Award | 270,000 | $30 |
| Jan 13, 2026 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | A-Award | 90,000 | $30 |
| Jan 13, 2026 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | A-Award | 60,000 | $0.00 |
| Jan 2, 2026 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | Purchase | 9,680 | $26 |
| Jan 2, 2026 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | F-InKind | 154 | $27 |
| Jan 2, 2026 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 375 | $0.00 |
| Jan 2, 2026 | Wagner Paul A. · director, officer: SEE REMARKS | F-InKind | 164 | $27 |
| Jan 2, 2026 | Wagner Paul A. · director, officer: SEE REMARKS | M-Exempt | 1,250 | $0.00 |
| Oct 2, 2025 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | F-InKind | 134 | $15 |
| Oct 2, 2025 | Riley Antony A · officer: CHIEF FINANCIAL OFFICER | M-Exempt | 375 | $0.00 |
| Oct 2, 2025 | Wagner Paul A. · director, officer: SEE REMARKS | M-Exempt | 1,250 | $0.00 |
| Oct 2, 2025 | Wagner Paul A. · director, officer: SEE REMARKS | F-InKind | 98 | $15 |
| Jul 3, 2025 | Wagner Paul A. · director, officer: SEE REMARKS | M-Exempt | 1,250 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 52Increased 52Reduced 38Sold out 13
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FEDERATED HERMES, INC. | Increased | 2,110,516 | Aug 12, 2026 |
| FEDERATED HERMES, INC. | Unchanged | 1,765,516 | May 11, 2026 |
| ORBIMED ADVISORS LLC | Increased | 1,577,705 | Aug 14, 2026 |
| FRED ALGER MANAGEMENT, LLC | Increased | 1,439,697 | Aug 14, 2026 |
| Jupiter Topco LLC | New Position | 1,373,060 | Aug 14, 2026 |
| FRED ALGER MANAGEMENT, LLC | Reduced | 1,273,965 | May 15, 2026 |
| BlackRock, Inc. | Increased | 1,222,862 | Aug 7, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 1,196,955 | May 15, 2026 |
| JANUS HENDERSON GROUP PLC | Reduced | 1,188,060 | May 18, 2026 |
| Affinity Asset Advisors, LLC | Increased | 1,145,391 | Aug 13, 2026 |
| AFFINITY ASSET ADVISORS, LLC | Unchanged | 1,011,890 | May 14, 2026 |
| BIOIMPACT CAPITAL LLC | New Position | 1,000,682 | May 15, 2026 |
| MPM BioImpact LLC | Reduced | 987,448 | Aug 14, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Increased | 950,000 | May 15, 2026 |
| TCG Crossover Management, LLC | New Position | 920,000 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 6, 2026